Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–78 of 78 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Study of Milk Allergy and Tolerance in Children

NCT00778258
Conditions
Food Hypersensitivity, Milk Hypersensitivity
Interventions
Baked Milk, Non-baked Milk
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 10 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Frontotemporal Dementia, Right Sided Cerebral Hemisphere Cerebrovascular Accident
Interventions
Brain HQ
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Aggression
Interventions
Friend to Friend program, Psychoeducational attention control intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Hyperkalemia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 89 Years
Enrollment
1,151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Not listed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Alcohol Sensitivity in AERD

NCT03441438
Conditions
Aspirin-Sensitive Asthma With Nasal Polyps, Samter's Syndrome
Interventions
Water, Red wine, Polyphenolic Compounds
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia